Try
Bausch Health Companies Inc.
BHCUnited States
85 filed reports · 626 financial concepts · 1 earnings calls · 0 media appearances
Filed reports
85 reports · Dec 2015 to Jun 2026Each report counts once it has at least one extracted financial fact. Also extracted from these reports: 113 guidance figures.
| Report type | Reports | Facts | Periods |
|---|---|---|---|
| Current · 8-KSEC EDGAR | 41 | 113 | Mar 2016 to Jun 2026 |
| Quarterly · 10-QSEC EDGAR | 32 | 8,437 | Mar 2016 to Jun 2026 |
| Annual · 10-KSEC EDGAR | 11 | 7,860 | Dec 2015 to Dec 2025 |
| Quarterly · 10-Q/ASEC EDGAR | 1 | 1 | Jun 2022 |
Documents
| Period | Type | Period end | Published | Facts | Source |
|---|---|---|---|---|---|
| FY2026 Q2 | 10-Q | Jun 30, 2026 | Jul 30, 2026 | 500 | Open |
| FY2026 Q2 | 8-K | Jun 30, 2026 | Jul 29, 2026 | 4 | Open |
| FY2026 Q1 | 10-Q | Mar 31, 2026 | Apr 30, 2026 | 364 | Open |
| FY2026 Q1 | 8-K | Mar 31, 2026 | Apr 29, 2026 | 4 | Open |
| FY2025 | 10-K | Dec 31, 2025 | Feb 19, 2026 | 1,439 | Open |
| FY2025 Q4 | 8-K | Dec 31, 2025 | Feb 18, 2026 | 4 | Open |
| FY2025 Q3 | 10-Q | Sep 30, 2025 | Oct 30, 2025 | 341 | Open |
| FY2025 Q3 | 8-K | Sep 30, 2025 | Oct 29, 2025 | 2 | Open |
| FY2025 Q2 | 10-Q | Jun 30, 2025 | Jul 31, 2025 | 206 | Open |
| FY2025 Q2 | 8-K | Jun 30, 2025 | Jul 30, 2025 | 2 | Open |
| FY2025 Q1 | 10-Q | Mar 31, 2025 | May 1, 2025 | 206 | Open |
| FY2025 Q1 | 8-K | Mar 31, 2025 | Apr 30, 2025 | 4 | Open |
Financial data
626 concepts · 16,411 factsEach concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.
Financial582 concepts · 12,020 facts · Jun 2013 to Jul 2026
- Costs and expenses63 · Dec 2013 to Jun 2026
- Net cash provided by used in operating activities63 · Dec 2013 to Jun 2026
- Operating income loss63 · Dec 2013 to Jun 2026
- Revenue63 · Dec 2013 to Jun 2026
- Accumulated other comprehensive income loss net of tax61 · Dec 2013 to Jun 2026
- Cash and cash equivalents at carrying value61 · Dec 2013 to Jun 2026
- Stockholders equity including portion attributable to noncontrolling interest61 · Dec 2013 to Jun 2026
- Gains losses on extinguishment of debt60 · Dec 2013 to Jun 2026
- Amortization of financing costs and discounts59 · Dec 2013 to Jun 2026
- Comprehensive income net of tax59 · Dec 2013 to Jun 2026
- Comprehensive income net of tax attributable to noncontrolling interest59 · Dec 2013 to Jun 2026
- Comprehensive income net of tax including portion attributable to noncontrolling interest59 · Dec 2013 to Jun 2026
- Deferred income taxes59 · Dec 2013 to Jun 2026
- Depreciation and amortization59 · Dec 2013 to Jun 2026
- Foreign currency transaction gain loss before tax59 · Dec 2013 to Jun 2026
- Gain loss related to litigation settlement59 · Dec 2013 to Jun 2026
- Goodwill (US GAAP)59 · Dec 2013 to Jun 2026
- Income tax expense benefit59 · Dec 2013 to Jun 2026
- Increase decrease in accounts payable and accrued liabilities59 · Dec 2013 to Jun 2026
- Increase decrease in accounts receivable59 · Dec 2013 to Jun 2026
- Increase decrease in inventories59 · Dec 2013 to Jun 2026
- Increase decrease in prepaid deferred expense and other assets59 · Dec 2013 to Jun 2026
- Investment income interest59 · Dec 2013 to Jun 2026
- Net cash provided by used in financing activities59 · Dec 2013 to Jun 2026
Segment30 concepts · 3,048 facts · Sep 2013 to Jun 2026
- Revenue1,401 · Dec 2013 to Jun 2026
- Operating income loss269 · Dec 2014 to Jun 2026
- Goodwill246 · Dec 2014 to Jun 2026
- Goodwill foreign currency translation gain loss223 · Dec 2015 to Jun 2026
- Cost of goods and services sold (US GAAP)140 · Dec 2022 to Jun 2026
- Goodwill acquired during period97 · Dec 2014 to Jun 2026
- Goodwill impairment loss95 · Sep 2016 to Jun 2026
- Goodwill other increase decrease72 · Dec 2016 to Dec 2022
- Research and development expense excluding acquired in process cost70 · Dec 2022 to Jun 2026
- Selling general and administrative expense70 · Dec 2022 to Jun 2026
- Payments to acquire productive assets66 · Dec 2013 to Dec 2023
- Operating Income52 · Sep 2017 to Jun 2026
- Total Assets43 · Dec 2014 to Mar 2018
- Goodwill transfers39 · Dec 2016 to Dec 2025
- Goodwill written off related to sale of business unit39 · Dec 2014 to Dec 2020
- Profit loss35 · Dec 2013 to Jun 2017
- Depreciation and amortization21 · Dec 2013 to Dec 2017
- Goodwill purchase accounting adjustments13 · Dec 2014 to Sep 2016
- Asset impairment charges12 · Dec 2014 to Dec 2017
- Goodwill translation adjustments10 · Dec 2014 to Sep 2016
- Number of reporting units10 · Mar 2016 to Sep 2022
- Bausch + Lomb/ International7 · Dec 2020
- Revenue (excluding assessed tax)5 · Mar 2025 to Jun 2026
- Revenue from contracts with customers (excluding tax)4 · Mar 2017 to Jun 2017
Geography3 concepts · 712 facts · Dec 2013 to Dec 2025
- Revenue693 · Dec 2013 to Dec 2025
- Accounts Receivable, Net15 · Dec 2015 to Dec 2024
- Loss contingency new claims filed number4 · Dec 2015
Product8 concepts · 518 facts · Dec 2013 to Jun 2026
- Revenue386 · Dec 2013 to Jun 2026
- Cost of goods and services sold (US GAAP)92 · Dec 2016 to Jun 2026
- Impairment of intangible assets finitelived16 · Sep 2015 to Mar 2025
- Intangible Assets (excluding Goodwill)15 · Sep 2017 to Dec 2020
- Impairment of intangible assets excluding goodwill6 · Dec 2017 to Dec 2018
- Asset impairment charges1 · Jun 2023
- Impairment of long lived assets to be disposed of1 · Dec 2016
- Xifaxan Branded Products1 · Sep 2022
Guidance3 concepts · 113 facts · Jun 2016 to Jul 2026
- Revenue Guidance83 · Jun 2016 to Jul 2026
- Revenue Growth Guidance24 · May 2022 to Jul 2026
- EPS (Diluted) Guidance6 · Jun 2016 to Nov 2016
Segments
4,278 factsFigures broken down by business line, region, product or another axis the company reports on.
Statement business segments46 members · 3,044 facts
- Salix427 · Dec 2016 to Jun 2026
- Bausch Lomb321 · Dec 2019 to Jun 2026
- International Rx321 · Dec 2019 to Jun 2026
- Solta Medical277 · Dec 2020 to Jun 2026
- Diversified Products254 · Dec 2016 to Dec 2023
- Diversified227 · Dec 2021 to Jun 2026
- Ortho Dermatologics217 · Dec 2016 to Dec 2022
- Baushand Lomb International203 · Sep 2015 to Dec 2020
- Bausch Lomb International106 · Dec 2014 to Dec 2022
- Salix segment63 · Sep 2017 to Jun 2026
- Developed Markets62 · Sep 2013 to Dec 2017
- Branded Rx60 · Sep 2015 to Mar 2018
- Emerging Markets57 · Dec 2013 to Dec 2017
- US Diversified Products54 · Sep 2015 to Mar 2018
- Branded RX40 · Dec 2014 to Dec 2018
- U.S. Diversified Products38 · Dec 2014 to Dec 2018
- Diversified products segment33 · Sep 2017 to Sep 2022
- Bausch lomb27 · Mar 2021 to Jun 2026
- International rx27 · Mar 2021 to Jun 2026
- Baushand lomb international segment24 · Dec 2015 to Sep 2020
- Ortho dermatologics segment23 · Mar 2018 to Sep 2022
- Solta medical segment22 · Mar 2022 to Jun 2026
- Diversified segment19 · Dec 2021 to Jun 2026
- Dermatology16 · Dec 2022 to Dec 2023
- Branded rx segment16 · Dec 2015 to Mar 2018
- Usdiversified products segment14 · Dec 2015 to Mar 2018
- Bausch lomb international11 · Dec 2015 to Dec 2020
- Bausch lomb international10 · Dec 2017 to Dec 2020
- Developed markets10 · Dec 2014 to Jun 2016
- Emerging markets10 · Dec 2014 to Jun 2016
- Total9 · Dec 2013 to Dec 2015
- Salix segment8 · Dec 2018 to Dec 2025
- Branded rx7 · Dec 2015 to Dec 2017
- Diversified products segment6 · Dec 2018 to Dec 2023
- U.s.diversified products segment6 · Dec 2015 to Dec 2017
- Ortho dermatologics segment4 · Dec 2018 to Dec 2021
- Bausch Lomb International Branded Rxand U.S. Diversified Products2 · Dec 2016
- Dermatology segment2 · Dec 2021 to Mar 2023
- Developed Markets Emerging Markets U.S. Reporting Segments2 · Dec 2016
- Bausch lomb international branded rxand u.s.diversified products2 · Sep 2016
- Developed markets emerging markets u.s.reporting segments2 · Sep 2016
- Bausch Lomb International And Branded RX Segments1 · Dec 2016
- U.s.diversified products segment1 · Dec 2017
- Branded Rx And U.S. Diversified Products Segments1 · Sep 2016
- Developed Marketsand Emerging Markets Segments1 · Dec 2016
- Developed Markets And Emerging Markets Segments1 · Dec 2016
Statement geographicalsrt:StatementGeographicalAxis19 members · 578 facts
- CA41 · Dec 2015 to Dec 2025
- CN40 · Dec 2016 to Dec 2025
- DE40 · Dec 2016 to Dec 2025
- ES40 · Dec 2016 to Dec 2025
- FR40 · Dec 2016 to Dec 2025
- GB40 · Dec 2016 to Dec 2025
- JP40 · Dec 2016 to Dec 2025
- MX40 · Dec 2016 to Dec 2025
- Other Countries40 · Dec 2016 to Dec 2025
- PL40 · Dec 2016 to Dec 2025
- RU40 · Dec 2016 to Dec 2025
- United Statesand Puerto Rico40 · Dec 2016 to Dec 2025
- IT37 · Dec 2016 to Dec 2025
- KR25 · Jun 2019 to Dec 2025
- EG24 · Dec 2016 to Dec 2021
- Argentina brazil egypt greece turkey ukraineand venezuela4 · Dec 2018 to Dec 2021
- Algeria argentina belarus brazil greece iran russia serbia south africa turkey ukraine and venezuela3 · Dec 2022 to Dec 2024
- Argentina belarus brazil greece russia serbia south africa turkey ukraine and venezuela2 · Dec 2021 to Dec 2022
- Greece portugal ukraine turkey egypt argentinaand brazil2 · Dec 2017 to Dec 2018
Product or servicesrt:ProductOrServiceAxis16 members · 449 facts
- Product92 · Dec 2016 to Jun 2026
- Product And Service Other88 · Dec 2016 to Jun 2026
- Price Appreciation Credit42 · Mar 2018 to Jun 2026
- Brandedand Other Generic Products40 · Dec 2016 to Dec 2025
- Device Products40 · Dec 2016 to Dec 2025
- Overthe Counter Products40 · Dec 2016 to Dec 2025
- Pharmaceutical Products40 · Dec 2016 to Dec 2025
- Other Revenues34 · Dec 2016 to Dec 2025
- Other Product Lines9 · Sep 2017 to Sep 2019
- Xifaxan6 · Dec 2018 to Dec 2020
- Xifaxan Branded Products5 · Sep 2022 to Mar 2025
- Products And Services Other4 · Sep 2017 to Sep 2018
- Uceris Foam4 · Jun 2023 to Dec 2023
- Arestin2 · Dec 2018
- Uceris2 · Dec 2018
- IBS Chek1 · Dec 2016
Statement geographicalus-gaap:StatementGeographicalAxis18 members · 134 facts
- CA12 · Dec 2013 to Jun 2018
- CN9 · Dec 2013 to Jun 2018
- DE9 · Dec 2013 to Jun 2018
- FR9 · Dec 2013 to Jun 2018
- GB9 · Dec 2013 to Jun 2018
- JP9 · Dec 2013 to Jun 2018
- MX9 · Dec 2013 to Jun 2018
- Other Countries9 · Dec 2013 to Jun 2018
- PL9 · Dec 2013 to Jun 2018
- RU9 · Dec 2013 to Jun 2018
- United Statesand Puerto Rico9 · Dec 2013 to Jun 2018
- EG8 · Dec 2014 to Jun 2018
- BR7 · Dec 2013 to Mar 2018
- AU5 · Dec 2013 to Dec 2017
- ES4 · Mar 2017 to Jun 2018
- IT4 · Mar 2017 to Jun 2018
- Greece spain italy portugal2 · Dec 2015 to Dec 2016
- Russia egypt italy brazil spain greeceand portugal2 · Dec 2016 to Dec 2017
Product or serviceus-gaap:ProductOrServiceAxis13 members · 69 facts
- Brandedand Other Generic Products9 · Dec 2013 to Jun 2018
- Device Products9 · Dec 2013 to Jun 2018
- Overthe Counter Products9 · Dec 2013 to Jun 2018
- Pharmaceutical Products9 · Dec 2013 to Jun 2018
- Uceris9 · Sep 2017 to Dec 2019
- Other Product Lines7 · Mar 2017 to Jun 2018
- Allianceand Royalty Servicesand Other Products5 · Dec 2013 to Dec 2017
- Uceris4 · Dec 2017 to Jun 2018
- Price Appreciation Credit2 · Mar 2018 to Jun 2018
- Product2 · Jun 2017 to Jun 2018
- Products And Services Other2 · Jun 2017 to Jun 2018
- Ezogabine Retigabine1 · Dec 2015
- Zelapar1 · Sep 2015
Subsegments3 members · 4 facts
- Salix Reporting Unit2 · Sep 2016 to Mar 2018
- Former United States Reporting Unit1 · Sep 2016
- Ortho Dermatologics Reporting Unit1 · Mar 2018
Text from filings
Management commentary and risk factors, extracted from SEC filings only.
No commentary or risk-factor text for this company.
Earnings calls
1 calls · Jul 2026Transcripts with management claims and analyst questions, one per fiscal period.
- FY2026 Q2Jul 29, 2026
Executive media
Podcasts, interviews and conference appearances by the company's executives, with their claims.
No media appearances for this company.
Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Oct 16, 2026) and refreshed every few hours.